Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00462579
Status:
COMPLETED
Last Update Posted:
2018-06-12
First Post:
2007-04-17
Brief Title:
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use 4 may be transmitted from person to person 5 and may be passed via environmental contamination 6 Surveillance for panresistant Acinetobacter species should be a priority given the lack of antibiotic options for the treatment of these infections There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task and the use of alternative antibiotics should be considered in ICUs where these strains are endemic
Detailed Description:
The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task and the use of alternative antibiotics should be considered in ICUs where these strains are endemiche following information will be collected age sex occupation hospital location at the time of positive culture ER medical ward ICU etc date of positive culture prior hospitalization receipt of outpatient dialysis home care or other regular medical care eg outpatient chemotherapy presence of invasive devices receipt of antibiotics including their type and whether they were adequate for the resistance profile of the organism prior positive microbiologic cultures time and location of positive cultures underlying diseases and severity of illness presence of urinary or intravascular devices recent immunomodulative therapies or radiation therapy physical exam findings laboratory and radiographical data antimicrobial usage within 30 days of onset of the infection microbiological data and resistance patterns choice of antibiotics once organism identified bacteriological outcomes laboratory results demographic information medications clinical outcomegender height weight ethnicity and past medical history We will collect information retrospectively
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None